| Project Detail |
The promoter, Nyxoah, is a listed company focused on the development and commercialisation of innovative solutions to treat moderate to severe Obstructive Sleep Apnea (OSA). Nyxoahs platform is based on the Genio system, a bilateral neurostimulation therapy able to stimulate both branches of the hypoglossal nerve.
Additionality and Impact
The project is aligned with the InvestEU objective of promoting research, development and innovation. The purpose of the loan is to provide direct venture debt financing to an innovative medtech company developing an innovative solution for patients with obstructive sleep apnea, an area with high unmet need.
By supporting the Promoter, the EIB enables the generation of European scientific knowledge and know-how while preserving and expanding highly skilled employment opportunities in Europe.
Currently, the Company does not have access to either non-dilutive or to long-term debt funding sources. The financing structure is adjusted to the investment needs of the Company, with a long tenor and deferred interest, minimising cash outflows. By contributing to the cash runway, EIB financing is expected to continue attracting investors and allow the company to accelerate its development. The project would not have been carried out to the same extent by the EIB without InvestEU support.
Objectives
The aim is to support the promoter in its research, development and innovation (RDI) activities related to implant solutions treating OSA.
Sector(s)
Industry - Manufacturing
Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 38 million
Total cost (Approximate amount)
EUR 84 million |
